Invest in Precision: Mitutoyo America Corporation Announces Limited-Time Savings on MiSTAR 555 and 575 Coordinate Measuring Machines
"The MiSTAR CMM is built to thrive on the shop floor. It is rugged, reliable and fully adaptable to your machining process. With this exclusive promotion, you're not just getting precision, you're getting value with savings of up to 26 percent."
Share
Mitutoyo's MCOSMOS software scales to meet your inspection needs, from basic measurement and reporting with MCOSMOS-1, to CAD model part programming with free-form surface evaluation MCOSMOS-2 and MCOSMOS-3 adds scanning of 2D line and 3D surface profiles with CAD model analysis.
Three configurations offered:
BASIC model type- PH6 TP20 probing and MCOSMOS-1 software for small shops with essential digital routines
Advanced model type- PH6M SP25 probe and MCOSMOS-2 software for growing operations who require CAD model part programming with free-form surface evaluation.
Ultimate model type- PH10 SP25 MCOSMOS-3 software for high-throughput environments
The Mitutoyo MiSTAR CMM delivers reliable performance across a broad range of operating environments with guaranteed accuracy from 10 °C to 40 °C, and enhanced capability within narrower ranges of 10 °C to 30 °C and 18 °C to 22 °C.
Each MiSTAR configuration is delivered ready for immediate operation and includes:
Professional installation by Mitutoyo factory-trained technicians, A2LA calibration and in-person training at a Mitutoyo Metrology Center
A complete hardware package featuring a power conditioner, calibration sphere and a workstation with computer system
A comprehensive probe stylus kit to support a range of measurement tasks
When accuracy matters, manufacturers turn to Mitutoyo for proven performance that drives quality forward. Contact your local Mitutoyo representative or distributor to schedule a demo, consultation, or get a quote.
At Mitutoyo, precision is our profession. We are the leader in metrology instruments, solutions and support, offering more than 5,500 products, the largest and most comprehensive product portfolio of any commercial metrology provider. Mitutoyo also has the highest-performing A2LA-accredited calibration laboratories (A2LA Certificate No. 0750.01) in the nation. For more information, contact the Mitutoyo inside sales team at mitutoyo.com/contact-us/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
UnitedHealth Group Announces Changes to Leadership Team
July 31, 2025--(BUSINESS WIRE)--UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date. "Wayne DeVeydt combines deep financial acumen and operating experience with the mission-oriented and compassionate approach to health care that is a perfect fit for UnitedHealth Group," said Stephen J. Hemsley, company chairman and chief executive officer. "John Rex has been an exceptional leader, having helped guide our company through substantial change with both strategic vision and strong commitment to our mission," said Hemsley. "I look forward to his continued insights as UnitedHealth Group moves forward." DeVeydt, 55, most recently has been a managing director and operating partner at Bain Capital, working with client leaders on operational improvement and growth acceleration. From 2018-2020, he was chairman and CEO of Surgery Partners, Inc. in Nashville, expanding the operational scale and financial performance of the surgical services firm. He joined Anthem, Inc. (now Elevance) in 2005 and served as its chief financial officer from 2007 to 2016. Prior to joining Anthem, DeVeydt served as a partner with PricewaterhouseCoopers LLP, with a focus on the health care sector. "There is no organization besides UnitedHealth Group that presents the kinds of opportunities to make a difference in health care, from individual patient care to broad system efficiency, so I am eagerly looking forward to joining the team," said DeVeydt. "I've been fortunate to know John Rex for over two decades and am honored to follow a leader of his caliber." Rex, 63, joined UnitedHealth Group as chief financial officer of the company's then newly established Optum business and previously had spent his career focused in health care across multiple roles and sectors. "This pivotal moment for UnitedHealth Group is the right time for a new yet greatly experienced executive like Wayne DeVeydt, and I look forward to supporting him and the entire leadership team while continuing to advise on a range of matters," said Rex. About UnitedHealth Group UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn. View source version on Contacts Media: uhgmedia@ UnitedHealth Group Media Sign in to access your portfolio
Yahoo
20 hours ago
- Yahoo
Citi Remains Bullish on Sana Biotechnology (SANA)
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best biotech penny stocks to buy right now. Citi analyst Samantha Semenkow maintained a bullish stance on Sana Biotechnology, Inc. (NASDAQ:SANA), giving it a Buy rating on July 2 with a $15 price target. A scientist working with a microscope in a laboratory, focusing on a cell of a medical experiment. The analyst based the rating on Sana Biotechnology, Inc.'s (NASDAQ:SANA) potential in addressing notable market opportunities. Semenkow stated that the company's Type 1 Diabetes (T1D) program has exhibited considerable proof-of-concept results, with updated six-month data showing durable c-peptide production and successful graft survival without the need for immunosuppression. According to the analyst, this data consistency bolsters confidence in Sana Biotechnology, Inc.'s (NASDAQ:SANA) approach and paints a positive picture for its T1D asset, SC451, anticipated to make progress towards an IND as early as 2026. The same day, Morgan Stanley analyst Maxwell Skor also assumed coverage of Sana Biotechnology, Inc. (NASDAQ:SANA) with an Overweight rating and $12 price target. The analyst expects an investigational new drug filing as early as next year for its proprietary HIP-modified, islet stem-cell derived T1D therapy, SC451. Sana Biotechnology (NASDAQ:SANA) is a biotechnology company that specializes in using engineered cells as medicines. It develops cell engineering programs that transform treatment across several therapeutic areas with treatment gaps, including diabetes, oncology, the central nervous system, and B-cell-mediated autoimmune disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
a day ago
- Miami Herald
Troubled handgun manufacturer files for Chapter 11 bankruptcy
The U.S. firearms industry has faced financial distress in 2025 as gun manufacturers and ammo producers have closed down and, in some cases, filed for bankruptcy protection. Several economic issues are the main reasons for the firearm industry's distress. Most companies blamed rising inflation, increased interest rates, and consumers' changing attitudes toward spending for their economic problems. Related: Popular music star's company files for Chapter 11 bankruptcy The industry's issues led to retail firearm sales declining in the first quarter of 2025 by 9.6% year-over-year with revenue dropping 11.5%, according to a report from RetailBI as American Rifleman reported. Rifle sales declined the most, by 12.3%, while handguns fell 9% and shotguns dropped by 7.5%. Rifle sales: 12.3% sales: 9% 7.5% sales: 9.6% decline. Some gun makers have also shut down operations for economic issues without filing for bankruptcy. In the case of firearms manufacturer SCCY Industries LLC, the company filed for Chapter 11 bankruptcy over four months after shutting down its operations. The Daytona Beach, Fla., firearms manufacturer filed its petition in the U.S. Bankruptcy Court for the Middle District of Florida on Aug. 1, listing $1 million to $10 million in assets and liabilities. The debtor's largest creditors include Center Point Business Park, owed over $599,000; County of Volusia, owed over $406,000, and BFB, owed over $283,000. Center Point Business Park, owed over $599, of Volusia, owed over $406, owed over $283,000. SCCY's assets were seized by the Volusia County Tax Office of Florida at its Daytona factory on March 11, 2025, for non-payment of tax debts of almost $250,000. The tax office posted a Notice of Pending Levy and Seizure on the factory's exterior stating: "All equipment, furniture, and fixtures located inside this location regardless of status (owned, leased, loaned, or borrowed,) are subjected to taxation and are now under pending levy and seizure for unpaid tangible personal property taxes." Joe Roebuck, a mechanical engineer and tool-and-die-maker, founded SCCY in 2003. SCCY's first manufactured gun, the CPX-1 pistol, was first sold in 2005. The company was listed in the Top 10 among domestic pistol manufacturers in volume in 2022, according to Shooting Illustrated. It is unclear what assets SCCY still possessed. More Bankruptcy: Major iconic food brand files for Chapter 11 bankruptcyPopular Dairy Queen rival franchisee files Chapter 11 bankruptcyPopular vision care chain files for Chapter 11 bankruptcy SCCY's bankruptcy follows a petition by a relatively new U.S. firearms manufacturer, Watchtower Firearms LLC, which filed for Chapter 11 bankruptcy on Feb. 27, 2025, facing financial problems. The debtor, which was established in 2022, said operational challenges, tax obligations, and significant vendor and service provider debt led to its financial distress. The Frisco, Texas, firearms maker offers its Apache 9mm pistol, its Bridger 7mm bolt-action rifle, and other custom and special edition rifles. Related: Popular beverage brand files Chapter 11 bankruptcy Firearms ammunition manufacturer and dealer Specialty Cartridge Inc., which operates as Atlanta Arms, filed for Chapter 11 bankruptcy protection on May 7, 2025, to reorganize its business. The company manufactures and sells ammunition for handguns and rifles, and offers hats and t-shirts for sale. It has various targets and target pasters for purchase as well. Most recently, firearms, ammunition, and indoor range retailer Bare Arms LLC filed for Chapter 11 bankruptcy protection for the second time in two years on July 21, 2025, because of financial distress. The debtor's petition did not state a specific reason for the bankruptcy filing, but it's likely that events leading up to Bare Arms' first Chapter 11 filing on May 15, 2023, played a role in its second bankruptcy filing. Don't miss the move: Subscribe to TheStreet's free daily newsletter The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
